SML3792
MRIA9 Trifluoroacetate
≥96% (HPLC)
别名:
8-(((2r,5r)-5-Amino-1,3-dioxan-2-yl)methyl)-6-(2-chloro-4-(3-fluoropyridin-2-yl)phenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate, 8-[(trans -5-Amino-1,3-dioxan-2-yl)methyl]-6-[2-chloro-4-(3-fluoro-2-pyridinyl)phenyl]-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one trifluoroacetate
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C24H22ClFN6O3 · xC2HF3O2
分子量:
496.92 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.21
MDL number:
Assay:
≥96% (HPLC)
Form:
powder
Storage condition:
desiccated
Quality Segment
assay
≥96% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
Fc1c(nccc1)c2cc(c(cc2)C3=Cc4c(nc(nc4)NC)N(C3=O)C[C@@H]5OC[C@H](CO5)N)Cl
InChI key
QKNBRNSGPNCARD-SGNKCFNYSA-N
Biochem/physiol Actions
ATP site-targeting, dual salt-inducible kinase (SIK1/2/3) & p21-activated kinase (PAK2/3) inhibitor with excellent selectivity over other kinases.
MRIA9 is an ATP site-targeting, dual salt-inducible kinase (SIK1/2/3 IC50 = 55/48/22 nM; SIK2/3 IC50 = 180/127 nM by cell-based NanoBRET) & p21-activated kinase (PAK2/3 IC50 = 41/140 nM; PAK1 IC50 = 580 nM) inhibitor with excellent selectivity over other kinases. MRIA9 sensitizes ovarian cancer cells to mitotic agent paclitaxel (Pac) treatment in SKOV3 cultures (1 nM Pac plus 0.5-5 µM MRIA9) and HeLa spheroids (2 nM Pac plus 5 µM MRIA9).
Disclaimer
Hygroscopic
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable